 Connection
Jens Kuhn to Antibodies, Viral
This is a "connection" page, showing publications Jens Kuhn has written about Antibodies, Viral.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.636 |
|
|
|
-
Kpetigo AD, Alexandre M, Camara A, Beavogui A, Doumbia S, Kieh M, Leigh B, Sow S, Wittkop L, Soutthiphong AA, Berry IM, Fleck S, Akoo P, Hamze B, Watson-Jones D, Kuhn JH, Greenwood B, Richert L, Yazdanpanah Y, Lévy Y, Thiébaut R, Prague M, Lhomme E. Effect of the time of day for vaccination on the immune response to Ebola Virus Disease vaccines: A modeling study from PREVAC randomized trial. PLoS Negl Trop Dis. 2026 Jan; 20(1):e0013950.
Score: 0.177
-
Chandrasekaran P, Berry IM, Callier V, Anthony SM, Hensley K, Kuhn JH, Shaw-Saliba K, Kennedy SB, Kieh M, Browne SM, Crozier I, Davey RT, Lane HC, Hensley LE, Follmann DA. Vector-Induced Humoral Responses After rVSV?G-ZEBOV-GP Immunization Identify Vaccinated Individuals and Correlate With Ebola Virus Glycoprotein Antibodies. J Infect Dis. 2025 Oct 15; 232(4):1004-1014.
Score: 0.173
-
Worwa G, Davis CW, Klim SE, Turcinovic J, Agans KN, Borisevich V, Geisbert JB, Cross RW, Crane A, Holbrook MR, Sanchez-Lockhart M, Kugelman JR, Patino Galindo JA, Geisbert TW, Ahmed R, Kuhn JH, Saphire EO, Palacios G, Crozier I. Monotherapy with antibody 1C3 partially protects Ebola virus-exposed macaques. J Virol. 2025 07 22; 99(7):e0029625.
Score: 0.169
-
Hastie KM, Salie ZL, Ke Z, Halfmann PJ, DeWald LE, McArdle S, Grinyó A, Davidson E, Schendel SL, Hariharan C, Norris MJ, Yu X, Chennareddy C, Xiong X, Heinrich M, Holbrook MR, Doranz B, Crozier I, Kawaoka Y, Branco LM, Kuhn JH, Briggs JAG, Worwa G, Davis CW, Ahmed R, Saphire EO. Anti-Ebola virus mAb 3A6 protects highly viremic animals from fatal outcome via binding GP(1,2) in a position elevated from the virion membrane. Nat Commun. 2025 Feb 03; 16(1):1293.
Score: 0.165
-
Valayer S, Alexandre M, Prague M, Beavogui AH, Doumbia S, Kieh M, Greenwood B, Leigh B, Poupelin M, Schwimmer C, Sow SO, Berry IM, Kuhn JH, Fusco D, Cauwelaert ND, Watson-Jones D, Thiébaut R, Lévy Y, Yazdanpanah Y, Richert L, Lhomme E. Evaluation of waning of IgG antibody responses after rVSV?G-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial. Emerg Microbes Infect. 2025 Dec; 14(1):0.
Score: 0.163
-
Davey RT, Collins GL, Rouphael N, Poliquin G, McConnell R, Grubbs G, Moir SL, Langley JM, Teitelbaum M, Hewlett AL, McLellan SLF, Bhadelia N, Raabe VN, Mulligan MJ, Maljkovic Berry I, Dighero-Kemp B, Kurtz JR, Hensley LE, Dozier NCE, Marron LCB, DuChene A, Kuhn JH, Brown SK, Khurana S, Lane HC, Neaton JD. Safety and immunogenicity of a delayed booster dose of the rVSV?G-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial. Lancet Microbe. 2024 11; 5(11):100923.
Score: 0.161
-
Milligan JC, Davis CW, Yu X, Ilinykh PA, Huang K, Halfmann PJ, Cross RW, Borisevich V, Agans KN, Geisbert JB, Chennareddy C, Goff AJ, Piper AE, Hui S, Shaffer KCL, Buck T, Heinrich ML, Branco LM, Crozier I, Holbrook MR, Kuhn JH, Kawaoka Y, Glass PJ, Bukreyev A, Geisbert TW, Worwa G, Ahmed R, Saphire EO. Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. Cell. 2022 03 17; 185(6):995-1007.e18.
Score: 0.135
-
Postnikova EN, Pettitt J, Van Ryn CJ, Holbrook MR, Bollinger L, Yú S, Caì Y, Liang J, Sneller MC, Jahrling PB, Hensley LE, Kuhn JH, Fallah MP, Bennett RS, Reilly C. Scalable, semi-automated fluorescence reduction neutralization assay for qualitative assessment of Ebola virus-neutralizing antibodies in human clinical samples. PLoS One. 2019; 14(8):e0221407.
Score: 0.113
-
Kugelman JR, Kugelman-Tonos J, Ladner JT, Pettit J, Keeton CM, Nagle ER, Garcia KY, Froude JW, Kuehne AI, Kuhn JH, Bavari S, Zeitlin L, Dye JM, Olinger GG, Sanchez-Lockhart M, Palacios GF. Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail. Cell Rep. 2015 Sep 29; 12(12):2111-20.
Score: 0.086
-
Ou W, Delisle J, Jacques J, Shih J, Price G, Kuhn JH, Wang V, Verthelyi D, Kaplan G, Wilson CA. Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain. Virol J. 2012 Jan 25; 9:32.
Score: 0.067
-
Ou W, Delisle J, Konduru K, Bradfute S, Radoshitzky SR, Retterer C, Kota K, Bavari S, Kuhn JH, Jahrling PB, Kaplan G, Wilson CA. Development and characterization of rabbit and mouse antibodies against ebolavirus envelope glycoproteins. J Virol Methods. 2011 Jun; 174(1-2):99-109.
Score: 0.063
-
Iglesias AA, Períolo N, Bellomo CM, Lewis LC, Olivera CP, Anselmo CR, García M, Coelho RM, Alonso DO, Dighero-Kemp B, Sharma H, Kuhn JH, Di Paola N, Sanchez-Lockhart M, Palacios G, Schierloh LP, Martínez VP. Delayed viral clearance despite high number of activated T cells during the acute phase in Argentinean patients with hantavirus pulmonary syndrome. EBioMedicine. 2022 Jan; 75:103765.
Score: 0.033
-
Liu J, Babka AM, Kearney BJ, Radoshitzky SR, Kuhn JH, Zeng X. Molecular detection of SARS-CoV-2 in formalin-fixed, paraffin-embedded specimens. JCI Insight. 2020 06 18; 5(12).
Score: 0.030
-
Cornish JP, Moore IN, Perry DL, Lara A, Minai M, Promeneur D, Hagen KR, Virtaneva K, Paneru M, Buechler CR, O'Connor DH, Bailey AL, Cooper K, Mazur S, Bernbaum JG, Pettitt J, Jahrling PB, Kuhn JH, Johnson RF. Clinical Characterization of Host Response to Simian Hemorrhagic Fever Virus Infection in Permissive and Refractory Hosts: A Model for Determining Mechanisms of VHF Pathogenesis. Viruses. 2019 01 15; 11(1).
Score: 0.027
-
Buechler C, Semler M, Baker DA, Newman C, Cornish JP, Chavez D, Guerra B, Lanford R, Brasky K, Kuhn JH, Johnson RF, O'Connor DH, Bailey AL. Subclinical Infection of Macaques and Baboons with A Baboon Simarterivirus. Viruses. 2018 12 10; 10(12).
Score: 0.027
-
Clarke EC, Collar AL, Ye C, Caì Y, Anaya E, Rinaldi D, Martinez B, Yarborough S, Merle C, Theisen M, Wada J, Kuhn JH, Bradfute SB. Production and Purification of Filovirus Glycoproteins in Insect and Mammalian Cell Lines. Sci Rep. 2017 11 08; 7(1):15091.
Score: 0.025
-
Ng M, Ndungo E, Jangra RK, Cai Y, Postnikova E, Radoshitzky SR, Dye JM, Ramírez de Arellano E, Negredo A, Palacios G, Kuhn JH, Chandran K. Cell entry by a novel European filovirus requires host endosomal cysteine proteases and Niemann-Pick C1. Virology. 2014 Nov; 468-470:637-646.
Score: 0.020
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|